Clinical Cardio-oncology is a comprehensive, clinically focused title for cardiologists, oncologists, and specialists in cardio-oncology programs who need up-to-date knowledge about the cardiovascular effects of cancer treatment, especially on long-term cancer survivors. This brand-new resource covers the implementation of cardio-oncology into your practice, while a strong focus on patient management offers helpful information on coordinating care before, during, and after therapy. Its highly organized four-section format allows readers to quickly and easily locate relevant information. This Expert Consult version allows you to search all of the text, figures, images, and references from the book on a variety of devices, and it includes online case studies focused on the structure and implementation of cardio-oncology care.
1. Introduction - p. xvii 2. Video - p. xxi 3. Section 1: Oncology and Hematology Principles for the Cardiologist - p. xxi 4. Chapter 1. Principles of Cancer Treatment - p. 1 5. Chapter 2. Introduction to Systemic Antineoplastic Treatments for Cardiologists - p. 15 6. Chapter 3. Basics of Radiation Therapy - p. 39 7. Chapter 4. Cardiac Tumors: Overview and Pathology - p. 61 8. Chapter 5. Cardiac Tumors: Imaging - p. 77 9. Chapter 6. Cardiac Tumors: Treatment - p. 91 10. Chapter 7. Subtypes of Cancer Involving the Heart - p. 121 11. Section 2: Cardiac Complications from Cancer Therapy - p. 131 12. Chapter 8. Chemotherapy-Induced Cardiomyopathy - p. 133 13. Chapter 9. Vascular Toxicities of Cancer Therapies - p. 163 14. Chapter 10. Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors - p. 185 15. Introduction - p. 185 16. Vascular endothelial growth factor, vascular endothelial growth factor receptors, and signaling - p. 185 17. Vascular endothelial growth factor, vascular function, and angiogenesis - p. 187 18. Vascular endothelial growth factor inhibitors as antiangiogenic therapy - p. 188 19. Hypertension associated with antiangiogenic therapy - p. 190 20. Pathogenesis of hypertension induced by vascular endothelial growth factor inhibition - p. 190 21. Biomarkers to predict vascular endothelial growth factor inhibition–associated hypertension - p. 195 22. Management and therapy of vascular endothelial growth factor inhibitor–induced hypertension - p. 196 23. Initiation of antihypertensive therapy - p. 197 24. Hypertension as a surrogate of antivascular endothelial growth factor cancer treatment - p. 202 25. Mammalian target of rapamycin inhibitors, taxanes, and tyrosine kinase inhibitors used for hematologic malignancy - p. 203 26. Summary - p. 203 27. Case Study - p. 204 28. Chapter 11. Thromboembolic Disease in Cancer - p. 213 29. Chapter 12. Pericardial Disease and Effusion - p. 227 30. Chapter 13. Arrhythmias and QTc Prolongations - p. 245 31. Chapter 14. Radiation-Induced Heart Disease: Long-Term Manifestations, Diagnosis, and Management - p. 271 32. Chapter 15. Miscellaneous Syndromes (Takotsubo's, Orthostasis, and Differentiation Syndrome) - p. 291 33. Section 3: Coordination of Care at Different Stages of Cancer Treatment - p. 312 34. Chapter 16. Diagnostic Tests in Cardio-oncology - p. 313 35. Chapter 17. Pretherapy Cardiology Evaluation - p. 345 36. Introduction - p. 345 37. Precancer therapy cardiovascular evaluation - p. 345 38. Cardio-oncology evaluation before cancer surgery, endoscopic and interventional radiology procedures - p. 346 39. Cardio-oncology evaluation before cancer chemotherapy - p. 352 40. Cardio-oncology evaluation before transplantation - p. 364 41. Appendix 1. Case 1 - p. 369 42. Supplementary data - p. 370 43. Chapter 18. Intratherapy Cardiology Evaluation - p. 379 44. Chapter 19. Cardiovascular Effects of Anthracycline Chemotherapy and Radiation Therapy in Children with Cancer - p. 397 45. Introduction - p. 397 46. Pathophysiology of cardiovascular toxicity - p. 397 47. Radiotherapy - p. 399 48. Progression of cardiovascular toxicity - p. 401 49. Risk factors for cardiotoxicity - p. 404 50. Treatment-related risk factors - p. 404 51. Other risk factors for anthracycline cardiotoxicity - p. 404 52. Monitoring cardiotoxicity - p. 408 53. Other cardiovascular screening recommendations for late cardiovascular toxicity in long-term childhood cancer survivors - p. 410 54. Anthracycline-induced cardiotoxicity - p. 412 55. Management of cardiac morbidity in cancer survivors - p. 416 56. Summary - p. 421 57. Chapter 20. Supportive and Palliative Care and Issues in Cardio-oncology - p. 433 58. Section 4: Cardio-Oncology in Practice - p. 441 59. Chapter 21. Cardio-oncology in Practice: Goals and Principles - p. 443 60. Chapter 22. Structure and Implementation of Cardio-oncology Care - p. 445 61. Chapter 23. Cardio-oncology Fellowship Programs - p. 453 62. Appendix: Drug Guide - p. 465 63. Index - p. 477
Clinical Cardio-oncology is a comprehensive, clinically focused title for cardiologists, oncologists, and specialists in cardio-oncology programs who need up-to-date knowledge about the cardiovascular effects of cancer treatment, especially on long-term cancer survivors. This brand-new resource covers the implementation of cardio-oncology into your practice, while a strong focus on patient management offers helpful information on coordinating care before, during, and after therapy. Its highly organized four-section format allows readers to quickly and easily locate relevant information. This Expert Consult version allows you to search all of the text, figures, images, and references from the book on a variety of devices, and it includes online case studies focused on the structure and implementation of cardio-oncology care.
1. Introduction - p. xvii 2. Video - p. xxi 3. Section 1: Oncology and Hematology Principles for the Cardiologist - p. xxi 4. Chapter 1. Principles of Cancer Treatment - p. 1 5. Chapter 2. Introduction to Systemic Antineoplastic Treatments for Cardiologists - p. 15 6. Chapter 3. Basics of Radiation Therapy - p. 39 7. Chapter 4. Cardiac Tumors: Overview and Pathology - p. 61 8. Chapter 5. Cardiac Tumors: Imaging - p. 77 9. Chapter 6. Cardiac Tumors: Treatment - p. 91 10. Chapter 7. Subtypes of Cancer Involving the Heart - p. 121 11. Section 2: Cardiac Complications from Cancer Therapy - p. 131 12. Chapter 8. Chemotherapy-Induced Cardiomyopathy - p. 133 13. Chapter 9. Vascular Toxicities of Cancer Therapies - p. 163 14. Chapter 10. Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors - p. 185 15. Introduction - p. 185 16. Vascular endothelial growth factor, vascular endothelial growth factor receptors, and signaling - p. 185 17. Vascular endothelial growth factor, vascular function, and angiogenesis - p. 187 18. Vascular endothelial growth factor inhibitors as antiangiogenic therapy - p. 188 19. Hypertension associated with antiangiogenic therapy - p. 190 20. Pathogenesis of hypertension induced by vascular endothelial growth factor inhibition - p. 190 21. Biomarkers to predict vascular endothelial growth factor inhibition–associated hypertension - p. 195 22. Management and therapy of vascular endothelial growth factor inhibitor–induced hypertension - p. 196 23. Initiation of antihypertensive therapy - p. 197 24. Hypertension as a surrogate of antivascular endothelial growth factor cancer treatment - p. 202 25. Mammalian target of rapamycin inhibitors, taxanes, and tyrosine kinase inhibitors used for hematologic malignancy - p. 203 26. Summary - p. 203 27. Case Study - p. 204 28. Chapter 11. Thromboembolic Disease in Cancer - p. 213 29. Chapter 12. Pericardial Disease and Effusion - p. 227 30. Chapter 13. Arrhythmias and QTc Prolongations - p. 245 31. Chapter 14. Radiation-Induced Heart Disease: Long-Term Manifestations, Diagnosis, and Management - p. 271 32. Chapter 15. Miscellaneous Syndromes (Takotsubo's, Orthostasis, and Differentiation Syndrome) - p. 291 33. Section 3: Coordination of Care at Different Stages of Cancer Treatment - p. 312 34. Chapter 16. Diagnostic Tests in Cardio-oncology - p. 313 35. Chapter 17. Pretherapy Cardiology Evaluation - p. 345 36. Introduction - p. 345 37. Precancer therapy cardiovascular evaluation - p. 345 38. Cardio-oncology evaluation before cancer surgery, endoscopic and interventional radiology procedures - p. 346 39. Cardio-oncology evaluation before cancer chemotherapy - p. 352 40. Cardio-oncology evaluation before transplantation - p. 364 41. Appendix 1. Case 1 - p. 369 42. Supplementary data - p. 370 43. Chapter 18. Intratherapy Cardiology Evaluation - p. 379 44. Chapter 19. Cardiovascular Effects of Anthracycline Chemotherapy and Radiation Therapy in Children with Cancer - p. 397 45. Introduction - p. 397 46. Pathophysiology of cardiovascular toxicity - p. 397 47. Radiotherapy - p. 399 48. Progression of cardiovascular toxicity - p. 401 49. Risk factors for cardiotoxicity - p. 404 50. Treatment-related risk factors - p. 404 51. Other risk factors for anthracycline cardiotoxicity - p. 404 52. Monitoring cardiotoxicity - p. 408 53. Other cardiovascular screening recommendations for late cardiovascular toxicity in long-term childhood cancer survivors - p. 410 54. Anthracycline-induced cardiotoxicity - p. 412 55. Management of cardiac morbidity in cancer survivors - p. 416 56. Summary - p. 421 57. Chapter 20. Supportive and Palliative Care and Issues in Cardio-oncology - p. 433 58. Section 4: Cardio-Oncology in Practice - p. 441 59. Chapter 21. Cardio-oncology in Practice: Goals and Principles - p. 443 60. Chapter 22. Structure and Implementation of Cardio-oncology Care - p. 445 61. Chapter 23. Cardio-oncology Fellowship Programs - p. 453 62. Appendix: Drug Guide - p. 465 63. Index - p. 477
